VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
284
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment

- VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos”
- Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability
- Company making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder

VistaGen Therapeutics (NASDAQ: VTGN) has reported new preclinical findings differentiating the mechanism of action of PH94B from that of benzodiazepines (https://nnw.fm/1rXwV). PH94B is an intranasal neuroactive steroid VistaGen is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder. As a solution to anxiety notably lacking the notorious side effects of traditional medications, the formulation could be a game-changer to the world of mental health.

“We are very pleased with the results of these studies that suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” said VistaGen CEO Shawn K. Singh. “While benzodiazepines provide relief for many Americans struggling with anxiety, the extremely risky safety profile does not lend itself to long-term use. The mechanism of action contributes to the safety profile.”

VistaGen, a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, reported that new in vitro electrophysiology data demonstrating that PH94B’s mechanism of action does not involve direct activation of GABA-A receptors. That is in direct contrast to the mechanism of action of benzodiazepines (benzos), which act as direct positive modulators of GABA-A receptors.

“As we have seen in Phase 2 clinical studies, while PH94B is able to produce rapid-onset benzo-like, anti-anxiety effects, this study demonstrates that PH94B does not have a benzo-like mechanism of action,” noted Singh. “As we approach Phase 3 development of PH94B, especially given the FDA’s recent public announcement about safety concerns associated with benzo use, these new data make us even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos.”

In additional news, VistaGen also provided business updates and released its financial results for the fiscal 2021 second quarter ended September 30, 2020 (https://nnw.fm/FchMK). Key highlights for the company included a positive FDA meeting that outlined the pathway to a key PH94B Phase 3 study beginning recruitment Q2 2021, along with news that the company had received more than $17.5 million in net proceeds from a public offering of common stock and a PH94B upfront license payment. The company also noted positive new data had been gathered from its second preclinical study of AV-101 in combination with probenecid.

“We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals,” observed Singh. “We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal.

“We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021,” he continued. “After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021.”

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.

For more information, visit the company’s website at www.VistaGen.com.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

VistaGen Therapeutics, Inc. (VTGN) Stock Research Links

VTGN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 204

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 180

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 61

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 182

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 191

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Coloplast A/S Highlights Impressive Full-Year Performance

Updated Category News Views 231

Coloplast A/S Financial Results Overview Coloplast A/S recently announced its full-year financial results for the fiscal year 2023/24, highlighting a solid performance characterized by growth and resilience across various business sectors. Their latest report demonstrates a robust organic growth rate of 8%, coupled with a notable EBIT margin of 27%. In monetary terms, the...

Continue Reading
Introducing Sproutr’s Innovative Program Placement Services

Updated Category News Views 200

Sproutr Unveils Comprehensive Program Placement Services Sproutr, a leading firm in insurance program design and product development, has launched its innovative Program Placement Services. This new offering aims to streamline the entire process of insurance program development, ensuring that it aligns well from the initial design to the final placement with carriers. The...

Continue Reading
Unstoppable Domains Introduces .DEMOS: Redefining Digital Identity

Updated Category News Views 147

Introducing .DEMOS: A New Era of Digital Identity In an exciting development, Unstoppable Domains has rolled out a new top-level domain, .DEMOS, in collaboration with Kynesys.xyz. This innovative domain is positioned as a Web3-first solution designed to foster connection and collaboration in a borderless internet landscape. The name .DEMOS is derived from the Greek term...

Continue Reading
Investors Urged to Join Class Action Against Open Lending Corporation

Updated Category News Views 193

Open Lending Corporation: A Call to Action for Affected Investors Investors suffering heavy losses in Open Lending Corporation (NASDAQ: LPRO) are presented with the chance to take action. It's an opportunity for those impacted by the recent financial discrepancies and corporate disclosures to become lead plaintiffs in a class action lawsuit. Class Action Lawsuit Details...

Continue Reading
McAfee Revolutionizes Digital Security with AI Techniques

Updated Category News Views 253

Innovative Protection: McAfee Leads in AI-Powered Security Recognized as a leader in online security, McAfee has become synonymous with consumer safety in a rapidly evolving digital landscape. With the escalation of online threats, including sophisticated deepfakes and scams, McAfee's advanced artificial intelligence capabilities make it the prime choice for individuals...

Continue Reading